Cns Pharmaceuticals Valuation
| CNSP Stock | USD 0.12 0.01 7.69% |
Cns Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of Cns Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 209.41 K, return on equity of -10.19, and Shares Owned By Insiders of 1.20 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cns Pharmaceuticals' valuation include:
Price Book 2.1332 | Enterprise Value 209.4 K | Enterprise Value Ebitda 0.4007 |
Undervalued
Today
Please note that Cns Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Cns Pharmaceuticals is based on 3 months time horizon. Increasing Cns Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cns Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 0.12, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.12 | Real 2.59 | Target 10.0 | Hype 0.13 | Naive 0.13 |
The intrinsic value of Cns Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cns Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cns Pharmaceuticals helps investors to forecast how Cns stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cns Pharmaceuticals more accurately as focusing exclusively on Cns Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cns Pharmaceuticals' intrinsic value based on its ongoing forecasts of Cns Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cns Pharmaceuticals' closest peers.
Cns Pharmaceuticals Cash |
|
Cns Valuation Trend
Cns Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Cns Pharmaceuticals' financial worth over time. Using both Cns Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Cns Valuation Data Drivers
Cns Pharmaceuticals Total Value Analysis
Cns Pharmaceuticals is currently projected to have valuation of 209.41 K with market capitalization of 5.28 M, debt of 300.81 K, and cash on hands of 8.96 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cns Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
209.41 K | 5.28 M | 300.81 K | 8.96 M |
Cns Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Cns is to check how much profit was generated for every dollar of assets it reports. Cns Pharmaceuticals shows a negative utilization of assets of -2.24 percent, losing $0.0224 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cns Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Cns Pharmaceuticals Ownership Allocation
Cns Pharmaceuticals holds a total of 40.75 Million outstanding shares. Almost 98.1 percent of Cns Pharmaceuticals outstanding shares are held by general public with 1.2 (percent) owned by insiders and only 0.7 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cns Pharmaceuticals Profitability Analysis
Net Loss for the year was (18.85 M) with profit before overhead, payroll, taxes, and interest of 0.About Cns Pharmaceuticals Valuation
The stock valuation mechanism determines Cns Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cns Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cns Pharmaceuticals. We calculate exposure to Cns Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cns Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.1 K | -4.3 K |
Cns Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cns Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 75.3 K |
Cns Pharmaceuticals Current Valuation Indicators
Cns Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Cns Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cns Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cns Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cns Pharmaceuticals' worth.Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.